Effect on Metabolic Parameters of Abilify in SPR
The Effects of Metabolic Parameters of Aripiprazole in Patients With Schizophrenia
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia.
The measurement of weight and lipid profile and fasting blood glucose will be measured at baseline and every 3 months for 1 year.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Shi Hyun Kang, MD
- Phone Number: 82-2-2204-0326
- Email: drshe@hanmail.net
Study Locations
-
-
-
Seoul, Korea, Republic of, 139-757
- Recruiting
- Seoul National Hospital
-
Contact:
- Jong-il Lee, M.D., Ph.D.
- Phone Number: 82-2-2204-0104
- Email: lji7542@hanmail.net
-
Seoul, Korea, Republic of, 039-757
- Recruiting
- Seoul National Hospital
-
Contact:
- Shi Hyun Kang, M.D.
- Phone Number: 82-2-2204-0326
- Email: drshe@hanmail.net
-
Principal Investigator:
- Jong il Lee, M.D.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- DSM-IV diagnosis with schizophrenia
- who signed an informed consent
Exclusion Criteria:
- comorbid with substance abuse or substance dependence
- pregnancy or lactation
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
observational
patients with schizophrenia who want to change an antipsychotics due to metabolic side effect
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
weight lipid profile : HDL, LDL, total-cholesterol, triglyceride fasting blood glucose
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
prolactin ECG
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Jong-il Lee, M.D., Seoul National Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- snh002
- MSABLI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
NCT07369401Not yet recruiting
-
NCT01190254CompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
NCT07184619Recruiting
-
NCT01190267CompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
NCT05944510CompletedTreatment Resistant Schizophrenia
-
NCT07626034Not yet recruiting